Leslie Williams, ImmusanT CEO [File photo]

Arch-backed Im­mu­sanT scraps PhII as celi­ac ther­a­py flops in a key test

Arch helped pro­vide Im­mun­sanT a $40 mil­lion round back in 2017 so it could af­ford a Phase II study for their lead ther­a­py to stave off celi­ac dis­ease. But that path wound up in a dead end to­day, as the start­up re­vealed that it’s de­cid­ed to aban­don their mid-stage pro­gram af­ter fail­ing to wit­ness any­thing like the ef­fi­ca­cy need­ed to go on.

Celi­ac dis­ease was Im­mu­sanT’s test case for a plat­form tech­nol­o­gy de­signed to cre­ate im­mune sys­tem tol­er­ance, us­ing a pep­tide-based ther­a­peu­tic vac­cine in an ap­proach they felt could be ap­plied in di­a­betes as well as oth­er au­toim­mune dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.